New Prostate Cancer Options You May Not Know About

Prostate cancer care goes beyond a Gleason score. Your cancer’s biology could change your treatment options. In Episode 5 of Keeping It Up with Dr. Mehan, Dr. Rahul Mehan joins medical oncologist and hematologist Dr. Wishwdeep Dhillon to explore genetic testing, biopsy warning signs, PSMA-targeted radiation with Pluvicto, and research on hormone therapy before surgery. They discuss why some men may need a team approach earlier, where focal therapy fits, and how treatment decisions balance cancer control with sexual function, urinary health, and quality of life. Follow Dr. Mehan: Instagram:   / doctor.mehan   TikTok:   / saved_by_the_balls   Chapters 0:00 - A New Era of Prostate Cancer Care 0:38 - Meet Dr. Wishwdeep Dhillon 3:58 - Same Gleason Score, Different Cancer Risk 5:20 - What Your Prostate Biopsy Can Reveal 9:49 - Can AI Help Assess Prostate Cancer Risk? 12:01 - Germline vs. Somatic Genetic Testing 15:28 - PARP Inhibitors and Earlier Treatment 21:11 - Tests Your Oncologist Wants to See 21:58 - Prostatectomy: Sexual and Urinary Side Effects 24:40 - Who Needs Surgery, and Who Can Wait? 26:31 - Active Surveillance and Focal Therapy 27:47 - Focal Therapy: Evidence and Insurance Barriers 33:53 - PSMA: From Finding Cancer to Targeting It 37:25 - Combining Treatments for Advanced Prostate Cancer 41:14 - PROTEUS: Hormone Therapy Before and After Surgery 45:47 - A High-Risk Patient and Treatment Before Surgery 48:58 - Ivermectin: What These Doctors Have Seen 50:38 - Diet, Exercise, and Hormone Therapy Side Effects 52:40 - Rapid Fire: PTEN, BRCA2, and Genetic Testing 55:39 - Actinium Trials: What Could Come Next? 55:59 - Why Earlier Oncology Involvement Matters